Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide effect on food intake in obese subjects
NCT03041792Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Liraglutide with Placebo (2 arms). Primary endpoint: Change From Baseline in Mean Energy Intake During Ad Libitum Lunches at 6 weeks. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03041792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041792.